Tags

Type your tag names separated by a space and hit enter

Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.
Virology. 2014 Mar; 452-453:32-41.V

Abstract

The recent identification of a novel human coronavirus responsible of a SARS-like illness in the Middle-East a decade after the SARS pandemic, demonstrates that reemergence of a SARS-like coronavirus from an animal reservoir remains a credible threat. Because SARS is contracted by aerosolized contamination of the respiratory tract, a vaccine inducing mucosal long-term protection would be an asset to control new epidemics. To this aim, we generated live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol). In mice susceptible to measles virus, recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV. As compared to immunization with adjuvanted recombinant Ssol protein, recombinant MV induced stronger and Th1-biased responses, a hallmark of live attenuated viruses and a highly desirable feature for an antiviral vaccine.

Authors+Show Affiliations

Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France. Electronic address: nicolas.escriou@pasteur.fr.Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France.Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France.Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France.Institut Pasteur, Unité de Biologie des Infections Virales Emergentes, Département de Virologie, F-69007 Lyon, France.Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France.Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France. Electronic address: frederic.tangy@pasteur.fr.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24606680

Citation

Escriou, Nicolas, et al. "Protection From SARS Coronavirus Conferred By Live Measles Vaccine Expressing the Spike Glycoprotein." Virology, vol. 452-453, 2014, pp. 32-41.
Escriou N, Callendret B, Lorin V, et al. Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology. 2014;452-453:32-41.
Escriou, N., Callendret, B., Lorin, V., Combredet, C., Marianneau, P., Février, M., & Tangy, F. (2014). Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology, 452-453, 32-41. https://doi.org/10.1016/j.virol.2014.01.002
Escriou N, et al. Protection From SARS Coronavirus Conferred By Live Measles Vaccine Expressing the Spike Glycoprotein. Virology. 2014;452-453:32-41. PubMed PMID: 24606680.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. AU - Escriou,Nicolas, AU - Callendret,Benoît, AU - Lorin,Valérie, AU - Combredet,Chantal, AU - Marianneau,Philippe, AU - Février,Michèle, AU - Tangy,Frédéric, Y1 - 2014/01/28/ PY - 2013/10/21/received PY - 2013/11/07/revised PY - 2014/01/03/accepted PY - 2014/3/11/entrez PY - 2014/3/13/pubmed PY - 2014/5/28/medline KW - Coronavirus KW - Measles vaccine KW - Severe acute respiratory syndrome KW - Spike glycoprotein SP - 32 EP - 41 JF - Virology JO - Virology VL - 452-453 N2 - The recent identification of a novel human coronavirus responsible of a SARS-like illness in the Middle-East a decade after the SARS pandemic, demonstrates that reemergence of a SARS-like coronavirus from an animal reservoir remains a credible threat. Because SARS is contracted by aerosolized contamination of the respiratory tract, a vaccine inducing mucosal long-term protection would be an asset to control new epidemics. To this aim, we generated live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol). In mice susceptible to measles virus, recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV. As compared to immunization with adjuvanted recombinant Ssol protein, recombinant MV induced stronger and Th1-biased responses, a hallmark of live attenuated viruses and a highly desirable feature for an antiviral vaccine. SN - 1096-0341 UR - https://www.unboundmedicine.com/medline/citation/24606680/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0042-6822(14)00005-1 DB - PRIME DP - Unbound Medicine ER -